GlassScriptPhysician profile
Mitchell L Feldman
NPI 1467440271
$2,557.67
in general payments reported to CMS, 2019-2025
30 companies · $454 in 2025
The $454 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $159 · 2021: $301 · 2022: $140 · 2023: $342 · 2024: $311 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,042 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,042.49 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $723.45 | 2019-2025 | Aptima, Thinprep 2000 Processor, Novasure |
| Bayer Healthcare Pharmaceuticals INC. | $390.99 | 2019-2025 | |
| Astellas Pharma US INC | $312.55 | 2023-2025 | Veozah |
| Roche Diagnostics Corporation | $134.56 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $128.58 | 2021-2024 | |
| Abbvie INC. | $97.80 | 2019-2023 | |
| Avion Pharmaceuticals | $80.00 | 2020-2021 | |
| Daiichi Sankyo INC. | $68.17 | 2019 | |
| Sumitomo Pharma America, INC. | $52.04 | 2023-2024 | Myfembree |
| Dexcom, INC. | $48.47 | 2025 | Dexcom G6 Transmitter |
| Coopersurgical, INC. | $45.62 | 2019-2023 | Paragard T 380a |
| Minerva Surgical, INC | $44.72 | 2019 | |
| Organon LLC | $43.02 | 2022-2025 | Nexplanon |
| Myovant Sciences INC. | $41.36 | 2021-2022 | |
| Allergan, INC. | $34.39 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $31.84 | 2023 | |
| Lupin INC. | $30.14 | 2020-2021 | |
| Agile Therapeutics, INC. | $25.85 | 2021 | |
| Optumhealth Care Solutions, LLC | $24.08 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Aspira Women'S Health INC | $23.24 | 2019 | |
| Evofem Biosciences, INC. | $22.67 | 2021 | |
| Mylan Pharmaceuticals INC. | $22.41 | 2019 | |
| Biogen, INC. | $20.44 | 2025 | Zurzuvae |
| Exeltis, USA INC. | $20.33 | 2021 | |
| Therapeuticsmd, INC. | $19.31 | 2019 | |
| Ethicon US, LLC | $18.72 | 2024 | Surgicel Nu-Knit |
| Organogenesis INC. | $16.48 | 2025 | Nushield |
| Merck Sharp & Dohme LLC | $12.31 | 2019 | |
| Channel Medsystems, INC. | $12.25 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.